November 2018

Medovent belongs to KeriMedical. KeriMedical aims to develop and promote a full range of implants for hand and wrist surgery only. More about KeriMedical

February 2018

From now on KeriMedical is taking care of your Reaxon® orders, the shipping and the accounting. KeriMedical will provide you with information for the you and your patients. Customer Service: Marie-Dominique Elles Phone.: +49 (0) 211 53883 320/321 Fax: +49 (0) 211 53883 33 320/321

October 2017

KeriMedical is now a strong partner of Medovent GmbH and has exclusively acquired the license rights for the product line Reaxon® for orthopedic care.

May 2017

We are looking forward to join the 38. Symposium of the BG Klinik Ludwigshafen (Germany) at May the 13th 2017. Please find further information: Symposium BG Ludwigshafen  

April 2017

The Medovent team will be pleased to meet you during the 58. DAH Symposium in Münster (Germany) from May the 4th–6th 2017. Visit us at the booth. Please find further information: DAH 2017

December 2016

Reaxon® Nerve Guide and Reaxon® Direct are now available in France.

November 2016

With the CE-certification of Reaxon® Direct, the Reaxon® product family is expanding. Reaxon® Direct allows the tension-free supply of short nerve defects and offers an optimal protection against scar tissue and painful neuroma formation.  

March 2015

Reaxon® Nerve Guide is also available for surgeons in Austria, Italy, and Switzerland.

May 2014

Medovent has started a project on new designs for the treatment of digital nerve defects in collaboration with the Institute of Neuroanatomy at the Hannover Medical School.

January 2014

The chitosan nerve conduit Reaxon® Nerve Guide for the treatment of peripheral nerve injuries receives the CE certificate.

April 2013

Medoderm receives the CE certificate for Quractiv® Derm – the wound dressing made of Chitosan-FH02 developed in collaboration with Medovent.

February 2012

Medovent starts the commercialization of chitosan microfibers for biomedical research.

October 2011

As a partners of the European project BIOHYBRID, Medovent along with nine other institutions, hospitals and companies from Germany, Israel, Italy, Portugal, Spain, and Sweden, start the development of innovative conduits for the repair of peripheral nerves. Further information: BIOHYBRID

April 2011

Medovent successfully finishes the testing of a new coating process. Medical devices can be provided with a thin chitosan surface without altering the natural properties of the biomaterial.

November 2010

Medovent receives the EN ISO 13485 certificate for the production and development of chitosan-based medical devices.